Tanaka Shun, Hayakawa Mikito, Tasaki Kuniharu, Ono Ryohei, Hirata Koji, Hosoo Hisayuki, Ito Yoshiro, Marushima Aiki, Yamagami Hiroshi, Oshika Tetsuro, Matsumaru Yuji
Department of Stroke and Cerebrovascular Diseases, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba, Ibaraki 305-8576, Japan.
Department of Stroke and Cerebrovascular Diseases, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba, Ibaraki 305-8576, Japan; Department of Neurology, Institute of Medicine, University of Tsukuba, 1-1-1, Tenno-dai, Tsukuba, Ibaraki 305-8575, Japan.
Am J Emerg Med. 2025 Jan;87:216.e5-216.e9. doi: 10.1016/j.ajem.2024.11.017. Epub 2024 Nov 10.
Central retinal artery occlusion (CRAO) is an ophthalmic emergency characterized by sudden loss of vision with a low chance of spontaneous recovery. This case report presents a 49-year-old female with sudden right eye visual loss, diagnosed as non-arteritic CRAO. Fundoscopic examination revealed retinal pallor, and optical coherence tomography demonstrated edema of the inner retinal layer, consistent with CRAO. Brain magnetic resonance imaging (MRI) showed an acute ischemic lesion in the right occipital subcortex. The patient received intravenous recombinant tissue plasminogen activator (IV rt-PA) at a lower-than-standard dose of 0.6 mg/kg within 4 h and 17 min of symptom onset, resulting in significant visual improvement. Extensive etiological investigation, including transesophageal echocardiography, uncovered a large, high-risk patent foramen ovale (PFO), leading to the diagnosis of PFO-associated CRAO and concomitant embolic stroke. This case suggests the effectiveness of low-dose IV rt-PA in treating CRAO, which might offer comparable efficacy to the standard dose while potentially minimizing bleeding risks. It also emphasizes the importance of considering cardiac comorbidities, particularly PFO, in younger CRAO patients, and underscores the need for a multidisciplinary approach and comprehensive stroke-etiology workups in CRAO management. This report contributes to the limited evidence on CRAO treatment in Japan, particularly in the context of lower tPA dosing and associated cardiac abnormalities. It underscores the importance of early diagnosis, treatment, and thorough etiological investigation in improving outcomes for CRAO patients.
视网膜中央动脉阻塞(CRAO)是一种眼科急症,其特征为视力突然丧失且自发恢复的可能性较低。本病例报告介绍了一名49岁女性,她突然出现右眼视力丧失,被诊断为非动脉炎性CRAO。眼底镜检查显示视网膜苍白,光学相干断层扫描显示视网膜内层水肿,与CRAO相符。脑部磁共振成像(MRI)显示右侧枕叶皮质下有急性缺血性病变。该患者在症状发作后4小时17分钟内接受了低于标准剂量0.6mg/kg的静脉注射重组组织型纤溶酶原激活剂(IV rt-PA),视力得到显著改善。包括经食管超声心动图在内的广泛病因学调查发现了一个大的、高危的卵圆孔未闭(PFO),从而诊断为PFO相关的CRAO和并发栓塞性中风。本病例表明低剂量IV rt-PA治疗CRAO有效,其疗效可能与标准剂量相当,同时可能将出血风险降至最低。它还强调了在年轻的CRAO患者中考虑心脏合并症,特别是PFO的重要性,并强调了在CRAO管理中采用多学科方法和全面的中风病因检查的必要性。本报告为日本关于CRAO治疗的有限证据做出了贡献,特别是在较低tPA剂量和相关心脏异常的背景下。它强调了早期诊断、治疗和彻底的病因学调查对改善CRAO患者预后的重要性。